دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Artificial intelligence to finally enable precision medicine for the management of resected non-small-cell lung cancer
C. Chouaïd 1,2 *, S. Gendarme 1,2 & J.-B. Auliac
doi : 10.1016/j.annonc.2023.05.001
Volume 34, Issue 7, July 2023, Pages 565-566
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
F. Mosele 1,2 * & M. Di Maio
doi : 10.1016/j.annonc.2023.05.011
Volume 34, Issue 7, July 2023, Pages 567-568
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
G. Curigliano1,2* , K. Dunton3 , M. Rosenlund 3,4 , M. Janek 5 , J. Cathcart 6 , Y. Liu 6 , P. A. Fasching 7,8 & H. Iwata
doi : 10.1016/j.annonc.2023.04.516
Volume 34, Issue 7, July 2023, Pages 569-577
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
M. Rakaee 1,2,3* , S. Andersen3,4 , K. Giannikou1,5 , E.-E. Paulsen3,6 , T. K. Kilvaer 3,4 , L.-T. R. Busund 2,7 , T. Berg2,7 , E. Richardsen2,7 , A. P. Lombardi7 , E. Adib1,8 , M. I. Pedersen3 , M. Tafavvoghi 9 , S. G. F. Wahl 10,11 , R. H. Petersen 12,13 , A. L. Bondgaard14 , C. W. Yde15 , C. Baudet 15 , P. Licht 16 , M. Lund-Iversen17 , B. H. Gr?nberg 10,11 , L. Fjellbirkeland18 , ?. Helland 19,20,21 , M. P?hl 22 , D. J. Kwiatkowski 1,23y & T. Donnem
doi : 10.1016/j.annonc.2023.04.005
Volume 34, Issue 7, July 2023, Pages 578-588
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
D. Boiarsky1 , C. A. Lydon 2 , E. S. Chambers 3 , L. M. Sholl 4 , M. Nishino5 , F. Skoulidis 6 , J. V. Heymach6 , J. Luo7 , M. A. Awad2 , P. A. Janne3 , E. M. Van Allen 2,8,9 , D. A. Barbie 3 & N. I. Vokes
doi : 10.1016/j.annonc.2023.04.514
Volume 34, Issue 7, July 2023, Pages 589-604
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
P. A. Sutera 1 , A. C. Shetty2,3 , A. Hakansson 4 , K. Van der Eecken5 , Y. Song 2,3 , Y. Liu 4 , J. Chang 3 , V. Fonteyne 6 , A. A. Mendes7 , N. Lumen 6 , L. Delrue 8 , S. Verbeke 5 , K. De Man9 , Z. Rana3 , T. Hodges2,3 , A. Hamid10 , N. Roberts 11 , D. Y. Song1,12,13 , K. Pienta 12,13 , A. E. Ross 14 , F. Feng 15,16,17 , S. Joniau18 , D. Spratt19 , S. Gillessen20 , G. Attard21 , N. D. James 22,23 , T. Lotan7 , E. Davicioni 4 , C. Sweeney24 , P. T. Tran1,3 , M. P. Deek25* & P. Ost
doi : 10.1016/j.annonc.2023.04.515
Volume 34, Issue 7, July 2023, Pages 605-614
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib☆
C. Serrano 1,2* , S. Bauer 3 , D. G?mez-Peregrina 2 , Y.-K. Kang 4 , R. L. Jones 5 , P. Rutkowski 6 , O. Mir7 , M. C. Heinrich 8 , W. D. Tap 9 , K. Newberry 10 , A. Grassian 10 , H. Shi 10 , S. Bialick 11 , P. Sch?ffski 12 , M. A. Pantaleo 13 , M. von Mehren14 , J. C. Trent 11y & S. George
doi : 10.1016/j.annonc.2023.04.006
Volume 34, Issue 7, July 2023, Pages 615-625
Why will there never be a randomized trial for NTRK-rearranged tumors?
N. Penel1,2 *, L. Lebellec 1 & J.-Y. Blay3,4
doi : 10.1016/j.annonc.2023.04.001
Volume 34, Issue 7, July 2023, Pages 626-628
Comment on ‘Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study’ by Dr Steffie L. Groenland et al.
G. Rubovszky 1 * & L. Torday
doi : 10.1016/j.annonc.2023.04.004
Volume 34, Issue 7, July 2023, Pages 628-629
Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis�: [Annals of Oncology 33 (2022) 321-329]
G. Curigliano1,2* , V. Mueller 3 , V. Borges 4 , E. Hamilton 5 , S. Hurvitz6 , S. Loi 7 , R. Murthy8 , A. Okines 9 , E. Paplomata10 , D. Cameron 11 , L. A. Carey12 , K. Gelmon13 , G. N. Hortobagyi8 , I. Krop 14 , S. Loibl15 , M. Pegram16 , D. Slamon 6 , J. Ramos 17 , W. Feng 17 & E. Winer
doi : 10.1016/j.annonc.2022.12.005
Volume 34, Issue 7, July 2023, Page 630
Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up�: [Annals of Oncology volume 31 (2020) 1476-1490]
M. Fassnacht 1,2 , G. Assie3,4 , E. Baudin5 , G. Eisenhofer6 , C. de la Fouchardiere7 , H. R. Haak8,9,10 , R. de Krijger 11,12 , F. Porpiglia 13,14 , M. Terzolo 15 & A. Berruti 16 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.12.006
Volume 34, Issue 7, July 2023, Page 631
Corrigendum to “Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma�: [Annals of Oncology 33 (2022) 1134-1148]
J. E. Augustin1,2,3 , P. Soussan 4,5 & A. J. Bass
doi : 10.1016/j.annonc.2023.01.001
Volume 34, Issue 7, July 2023, Page 632
Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)�: [Annals of Oncology 33 (2022) S1462-S1463]
D. Oh 1* , A. R. He 2 , S. Qin3 , L. Chen 4 , T. Okusaka5 , A. Vogel 6 , J. W. Kim 7 , T. Suksombooncharoen 8 , M. A. Lee9 , M. Kitano10 , H. A. Burris11 , M. Bouattour12 , S. Tanasa 13 , R. E. Zaucha14 , A. Avallone 15 , J. E. Cundom 16 , N. Rokutanda 17 , M. _Zotkiewicz18 , G. Cohen17 & J. W. Valle19
doi : 10.1016/j.annonc.2023.02.001
Volume 34, Issue 7, July 2023, Page 633
Corrigendum to “HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade�: [Annals of Oncology volume 33 (2022) 728-738]
X. M. Shao1,2 , J. Huang 1 , N. Niknafs 3 , A. Balan 3 , C. Cherry3 , J. White 3 , V. E. Velculescu1,3 , V. Anagnostou 3* & R. Karchin
doi : 10.1016/j.annonc.2023.04.003
Volume 34, Issue 7, July 2023, Page 634
